SciTech Development
4 SlideShares 1 Seguidor
Personal Information
Sector
Medical / Health Care / Pharmaceuticals
Sitio web
www.scitechdevelopment.com/
Acerca de
Clinical stage, biopharm company that has developed unique nano-delivery systems (SciTech Drug Delivery Vehicle - SDV) to enable intravenous (IV) delivery of water-insoluble drugs. One such challenged drug is fenretinide which has been shown in extensive clinical trials* to be a safe and effective anticancer therapy with targeted cancer destroying activity. The combination of the new SDV and fenretinide has led to SCI’s first drug product, ST-001 nanoFenretinide, that holds the promise of improving and saving many lives. SciTech's lead drug ST-001 is an IND approved immuno-oncology (IO), orphan drug, small molecule with an FDA roadmap to NDA post Phase 1b for multiple cancer indications
Etiquetas
fenretinide nanofenretinide st-001 scitech development drug drug delivery scitech cancer nanoparticle sdv oncology 4-hpr retinoid phospholipids mechanism of action timothy kuzel t-cell lymphoma sars-cov-2 antivirus antiviral covid-19 investigational new drug small cell lung cancer pharmaceutical brian leyland-jones scitech drug delivery vehicle io immuno-oncology opportunity clinic ready poster 4-hydroxy(phenyl)retinamide immunotherapeutic product pipeline active pharmaceutical ingredient louis m. scarmoutzos michael burns earle t. holsapple iii anticancer coronavirus hpr inflammation ards cytokine storm viremia therapeutic sars pediatric paediatric neuroblastoma leukemia ewing’s sarcoma family of tumours esft aml all acute myelogenous leukemia acute lymphocytic leukemia sclc orphan drug fda roadmap executive summary scientific formulation ralph e. parchment pharmaceutical development michael w. young elizabeth kraus clinical strategy christine d. copple andrew stumpf targeted cancer indications scitech delivery vehicle proprietary technology competiton bioavailability addressable market sizes r/r relapsed/refractory clinical trial phase 1a/1b fenretinide phospholipid suspension t-cell non-hodgkin's lymphoma ash 2019 steve munk senior scientists product development physicians oncologist kenneth massey john doux investor gregory kalemkerian executives clinicians board of advisors biotech advisory board chinese china abstract title china biomed innovation and investment conference cbic employment infrastructure savings cost of care economic development quality of life therapeutic reach drug costs cancer healthcare social impact economic impact social and economic impact socioeconomic faq fda approval innate agents immunotherapy treatment ancillary cancer remission cancer indications earle holsapple funding investment data driven snapshot redefining early stage investments resi synthetic lamellae multilayers bilayers self assembly molecular architecture triglyceride free self assemble retinoid receptors rar/rare oxygen radicals nanovesicle nanofenrtinide mitrochondrial oxphos des-1 deficient adaptive immunity ceramide inhibition apoptosis api ayad al-katib bioavailable suspension phospholipid agent ctcl non-hodgkin lymphoma testimonials
Ver más

Presentaciones

(2)

SciTech Development Company Presentation

Hace 4 años • 29 Visualizaciones

SciTech Development - Pediatric Oncology Focus

Hace 4 años • 40 Visualizaciones

Documentos

(2)

SciTech Development Testamonial Brochure

Hace 4 años • 43 Visualizaciones

ST-001 NanoFenretinide - SciTech Development Lead Drug Compound

Hace 4 años • 87 Visualizaciones
Personal Information
Sector
Medical / Health Care / Pharmaceuticals
Sitio web
www.scitechdevelopment.com/
Acerca de
Clinical stage, biopharm company that has developed unique nano-delivery systems (SciTech Drug Delivery Vehicle - SDV) to enable intravenous (IV) delivery of water-insoluble drugs. One such challenged drug is fenretinide which has been shown in extensive clinical trials* to be a safe and effective anticancer therapy with targeted cancer destroying activity. The combination of the new SDV and fenretinide has led to SCI’s first drug product, ST-001 nanoFenretinide, that holds the promise of improving and saving many lives. SciTech's lead drug ST-001 is an IND approved immuno-oncology (IO), orphan drug, small molecule with an FDA roadmap to NDA post Phase 1b for multiple cancer indications
Etiquetas
fenretinide nanofenretinide st-001 scitech development drug drug delivery scitech cancer nanoparticle sdv oncology 4-hpr retinoid phospholipids mechanism of action timothy kuzel t-cell lymphoma sars-cov-2 antivirus antiviral covid-19 investigational new drug small cell lung cancer pharmaceutical brian leyland-jones scitech drug delivery vehicle io immuno-oncology opportunity clinic ready poster 4-hydroxy(phenyl)retinamide immunotherapeutic product pipeline active pharmaceutical ingredient louis m. scarmoutzos michael burns earle t. holsapple iii anticancer coronavirus hpr inflammation ards cytokine storm viremia therapeutic sars pediatric paediatric neuroblastoma leukemia ewing’s sarcoma family of tumours esft aml all acute myelogenous leukemia acute lymphocytic leukemia sclc orphan drug fda roadmap executive summary scientific formulation ralph e. parchment pharmaceutical development michael w. young elizabeth kraus clinical strategy christine d. copple andrew stumpf targeted cancer indications scitech delivery vehicle proprietary technology competiton bioavailability addressable market sizes r/r relapsed/refractory clinical trial phase 1a/1b fenretinide phospholipid suspension t-cell non-hodgkin's lymphoma ash 2019 steve munk senior scientists product development physicians oncologist kenneth massey john doux investor gregory kalemkerian executives clinicians board of advisors biotech advisory board chinese china abstract title china biomed innovation and investment conference cbic employment infrastructure savings cost of care economic development quality of life therapeutic reach drug costs cancer healthcare social impact economic impact social and economic impact socioeconomic faq fda approval innate agents immunotherapy treatment ancillary cancer remission cancer indications earle holsapple funding investment data driven snapshot redefining early stage investments resi synthetic lamellae multilayers bilayers self assembly molecular architecture triglyceride free self assemble retinoid receptors rar/rare oxygen radicals nanovesicle nanofenrtinide mitrochondrial oxphos des-1 deficient adaptive immunity ceramide inhibition apoptosis api ayad al-katib bioavailable suspension phospholipid agent ctcl non-hodgkin lymphoma testimonials
Ver más